SMi Source lesson Oncology: Melanoma has the following microlearning topics
1. Learning Objectives
2. Introduction
3. Anatomy and Pathophysiology
4. Mechanisms of Disease Development and Progression: Genetic Mutations and Impact
5. Mechanisms of Disease Development and Progression: Immune Evasion and Immunosuppression, Angiogenesis
6. Mechanisms of Disease Development and Progression: Chemotherapy Resistance
7. Melanoma Risk Factors: UV Exposure and Compromised Immune System
8. Melanoma Risk Factors: Numerous Nevi and Genetics
9. Patient Demographics
10. Patient Demographics: Geography and Trends
11. Clinical Evaluation: Visual Examination
12. Clinical Examination: Cutaneous Melanoma
13. Clinical Examination: Ocular Melanoma
14. Superficial spreading melanoma
15. Clinical Examination: Melanoma Detection and Location
16. Clinical Examination: Lentigo Maligna Melanoma (LMM)
17. Clinical Examination: Acral Lentiginous Melanoma (ALM)
18. Clinical Examination: Biopsy
19. Clinical Examination: Lymph Node Involvement
20. Staging
21. Prognostic Factors and Survival: Ulceration and Tumor Depth, Lymph Node Involvement
22. Prognostic Factors and Survival: Factors and Statistics
23. NCCN Guidelines - I IIa, IIb, and IIc
24. NCCN Guidelines - Stage III and IV
25. Treatment of Early-Stage Primary Melanoma
26. Post-Surgical Adjuvant Therapy
27. Metastatic Melanoma
28. Response Rates of the Standard of Care Chemotherapies
29. Metastatic Melanoma: Combination and Biologic Therapies
30. Metastatic Melanoma: Biochemotherapy (BCT)
31. Advanced Stage IV Melanoma: Second-Line Therapy
32. Summary: Metastatic Melanoma Therapies
33. Overview: Clinical Trials in Different Patient Populations
34. Primary Melanoma IFN-α Adjuvant Therapy
35. Adjuvant Therapy Trials: ECOG
36. Adjuvant Therapy Trials: IFN-a
37. Metastatic Melanoma
38. Metastatic Melanoma: Single-Agent Chemotherapy
39. Metastatic Melanoma:Darthmouth Regimen
40. Metastatic Melanoma: CVD Regimen
41. Metastatic Melanoma: PC Combination Regimen
42. Metastatic Melanoma: Combination Regimens
43. Combination Chemotherapy Trials in Metastatic Melanoma
44. Combination Chemotherapy Trials in Metastatic Melanoma: Stage IV Melanoma
45. Metastatic Melanoma: Biologics
46. Metastatic Melanoma
47. Metastatic Melanoma: IL-2
48. Metastatic Melanoma: Biochemotherapy and Sequential vs. Concurrent BCT
49. Metastatic Melanoma: Biochemotherapy (BCT)
50. Metastatic Melanoma: BCT Pooled Analyses
51. Combination Strategies
52. Therapeutic Interventions Against Molecular Mechanisms of Melanoma Progression
53. Summary of Current and Investigational Agents: Classic Chemotherapeutics and Immunotherapies
54. Summary of Current and Investigational Agents: Targeted Agents, Vaccines, and Adoptive Cell Transfer
55. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation: c-Kit
56. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation: Importance of Combination Strategies
57. Targeting the Molecular Pathways Controlling Tumor Cell Proliferation
58. Investigational Clinical Trials
59. Pro-Apoptotic Agents & Chemosensitization to Overcome Drug Resistance: Chemosensitization
60. Pro-Apoptotic Agents & Chemosensitization to Overcome Drug Resistance: Pro-apoptotic Agents Under Investigation
61. Investigational Clinical Trials: Targeting Angiogenesis
62. Investigational Clinical Trials: Immunotherapy
63. Investigational Clinical Trials: Toll-Like Receptor Agonists
64. Investigational Clinical Trials: Adoptive Cell Therapy
65. Investigational Clinical Trials: Therapeutic Cancer Vaccines
66. Investigational Clinical Trials: Vaccines and New Targeted Therapies
67. Melanoma: Conclusions
